Axsome Therapeutics, Inc. (AXSM) vs Insulet Corp. (PODD)

A side-by-side comparison of Axsome Therapeutics, Inc. and Insulet Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Axsome Therapeutics, Inc. logo
AXSM
Axsome Therapeutics, Inc.
$9.11B
$177.08HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Insulet Corp. logo
PODD
Insulet Corp.
$9.39B
$135.62HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — AXSM vs PODD

growth of $100 · dividends reinvested · last 10y
AXSM +2054.3% (+35.9%/yr)PODD +242.0% (+13.1%/yr)AXSM compounded faster over this window
Log scale — wide-divergence pair
101001k10kStart $10020182020202220242026$2,154$342
AXSM PODD

AXSM vs PODD: by the numbers

  • •PODD is the larger company ($9.39B vs $9.11B market cap).
  • •PODD is profitable (12.29% net margin) while AXSM runs a net loss (-24.68%).

Metrics side by side

Valuation

MetricAXSMPODD
P/E ratioN/A25.35
Forward P/EN/A20.85
PEG ratioN/A0.25
P/S ratio11.733.08
P/B ratio109.396.61
EV / EBITDAN/A15.78
FCF yieldN/A3.18%

Profitability

MetricAXSMPODD
Gross margin93.24%71.08%
Operating margin-24.28%16.89%
Net margin-24.68%12.29%
ROE-230.05%26.39%
ROIC-50.82%16.04%

Growth (annualized)

MetricAXSMPODD
Revenue CAGR (5Y)N/A25.13%
EPS CAGR (5Y)N/A99.91%
Total return CAGR (5Y)41.40%-13.93%

Frequently asked

Is AXSM or PODD more profitable?
PODD runs the higher net margin — AXSM at -24.68% versus PODD at 12.29%.
How have AXSM and PODD total returns compared?
Over the past 10 years, AXSM delivered 35.76% and PODD delivered 13.11% annualized total return. Past performance doesn't predict future results.

Go deeper

Full AXSM analysisFull PODD analysisInteractive comparison tool

Dig into the metrics

Insulet P/E ratioAxsome Therapeutics ROEInsulet ROEAxsome Therapeutics operating marginInsulet operating marginAxsome Therapeutics revenue growthInsulet revenue growthAxsome Therapeutics free cash flowInsulet free cash flow

Axsome Therapeutics & Insulet appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.